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Abstract 
Background: Speckle‑type POZ protein (SPOP) is an E3 ubiquitin ligase adaptor protein that functions as a potential 
tumor suppressor, and SPOP mutations have been identified in ~10% of human prostate cancers. However, it remains 
unclear if mutant SPOP proteins can be utilized as biomarkers for early detection, diagnosis, prognosis or targeted 
therapy of prostate cancer. Moreover, the SPOP mutation sites are distributed in a relatively short region with multiple 
lysine residues, posing significant challenges for bottom‑up proteomics analysis of the SPOP mutations.
Methods: To address this issue, PRISM (high‑pressure, high‑resolution separations coupled with intelligent selection 
and multiplexing)‑SRM (selected reaction monitoring) mass spectrometry assays have been developed for quantify‑
ing wild‑type SPOP protein and 11 prostate cancer‑derived SPOP mutations.
Results: Despite inherent limitations due to amino acid sequence constraints, all the PRISM‑SRM assays developed 
using Arg‑C digestion showed a linear dynamic range of at least two orders of magnitude, with limits of quantification 
ranged from 0.1 to 1 fmol/μg of total protein in the cell lysate. Applying these SRM assays to analyze HEK293T cells 
with and without expression of the three most frequent SPOP mutations in prostate cancer (Y87N, F102C or F133V) 
led to confident detection of all three SPOP mutations in corresponding positive cell lines but not in the negative cell 
lines. Expression of the F133V mutation and wild‑type SPOP was at much lower levels compared to that of F102C and 
Y87N mutations; however, at present, it is unknown if this also affects the biological activity of the SPOP protein.
Conclusions: In summary, PRISM‑SRM enables multiplexed, isoform‑specific detection of mutant SPOP proteins in 
cell lysates, providing significant potential in biomarker development for prostate cancer.
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Background
Cancer is considered to be a genomic disease [1], and 
recent studies have identified mutations in speckle-type 
POZ protein (SPOP) in up to 15% of human primary 
prostate cancer (PCa) patients [2, 3]. SPOP mutations 
represent a distinct subclass of PCa, in that tumors with 
SPOP mutations generally lack other common features of 
PCa, including the PCa-specific TMPRSS2 and ETS fam-
ily gene rearrangements (present in ~50% of PCa), abnor-
malities in the phosphatidylinositide 3-kinase pathway, 
or deletion and mutations of the tumor suppressor gene 
TP53 [2, 4–6]. Therefore, the presence of mutant SPOP 
may serve as a specific protein biomarker for early detec-
tion of prostate carcinogenesis, particularly in patients 
lacking the TMPRSS2-ETS gene fusions. The qualita-
tive and quantitative study of mutant SPOP proteins can 
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contribute to improved understanding of the functional 
significance and molecular mechanism of SPOP muta-
tions in prostate cancer, and their relevance for targeted 
cancer therapies in clinical applications [7–11].
Currently available techniques for identification of 
SPOP mutation are mainly genomic methods, including 
whole-exome sequencing, Sanger sequencing, and quan-
titative RT-PCR [2, 12]. Although there have been several 
studies of the effects of forced over-expression of mutant 
SPOP protein in immortal cell lines [9–11], there appears 
to be no studies of endogenous SPOP mutations at the 
protein level in either primary prostate cancer cell lines 
or prostate cancer tissues, primarily due to the lack of 
antibodies capable of distinguishing between mutant and 
wild type SPOP protein. Traditional methods for protein 
measurement, which rely heavily on antibodies or other 
affinity reagents, are problematic for detection of SPOP 
mutations, for multiple reasons. First, most SPOP muta-
tions in PCa are missense mutations, in which only one 
amino acid is altered, so specific antibodies against the 
mutant epitopes are required to distinguish the mutant 
isoforms from the wild type SPOP protein. This is a dif-
ficult task, even in such well-studied missense mutant 
proteins as TP53 and KRAS [13]. Also, various mutations 
can occur in the same amino acid position; for example, 
the most frequently mutated residue of SPOP, F133, dis-
plays four types of variants (F→V/L/C/S), making the 
antibody development much more difficult [2]. Moreo-
ver, seven amino acid (AA) residues covering the 11 most 
frequent mutations are clustered in a 49-AA region in 
SPOP, making it extremely difficult to develop mutation-
specific antibodies in such an area. In this report we 
demonstrate that a highly sensitive targeted proteomic 
method, PRISM-SRM (high-pressure, high-resolution 
separations coupled with intelligent selection and mul-
tiplexing—selected reaction monitoring), is capable of 
providing quantitative information on both wild-type 
(WT) SPOP and four distinct single amino acid variants 
of SPOP that have been implicated in prostate cancer.
Mass spectrometry (MS)-based targeted proteom-
ics methods such as SRM have become an increasingly 
important strategy for detection and quantitation of pro-
teins in complex biological samples [14–18]. Combined 
with heavy isotope-labeled internal standards, targeted 
MS can provide highly sensitive and precise quantifi-
cation of protein isoforms with a difference as small 
as a single AA residue. An example of this approach 
is the use of SRM-MS to identify and quantify multi-
ple mutations of the Ras protein, either with enrich-
ment by immunoprecipitation [13, 19] or SDS-PAGE 
[20]. Compared to Ras mutations where only two adja-
cent AA residues are involved, the most frequent SPOP 
mutations are distributed at seven distinct positions 
within a 49-AA region (AA 87–135) [2], requiring mul-
tiple distinct probes to fully characterize mutant SPOP 
proteins. Moreover, there are multiple lysine residues in 
this region, producing very small tryptic peptides includ-
ing the mutated region that are unsuitable for bottom-up 
proteomics analysis. Herein, we describe the develop-
ment of new SPOP mutation-specific SRM assays for 
highly sensitive and multiplexed quantification of mul-
tiple SPOP protein isoforms using combined Arg-C 
digestion and PRISM-SRM. The PRISM-SRM method 
developed at our laboratory provides both increased 
loading and reduced complexity, leading to higher sensi-
tivity and specificity for low abundance protein quantifi-
cation. It has been successfully applied to the quantitative 
analysis of several PCa-associated biomarkers, such as 
prostate-specific antigen (PSA) [21, 22], AGR2 [23] and 
TMPRSS2-ERG fusion proteins [5, 24]. The validity of 
these PRISM-SRM assays for quantifying low abundance 
SPOP proteins was demonstrated using several SPOP 
mutant cell lines, providing an effective method for veri-
fying the mutant SPOP proteins as biomarkers in PCa.
Methods
Materials
Purified peptides (>97% purity) isotopically labeled 
with C-terminal  [13C615N2] lysine or  [13C615N4] arginine 
and their unlabeled counterparts were synthesized by 
Thermo Fisher Scientific (San Jose, CA). Urea, dithi-
othreitol (DTT), iodoacetamide (IAA) and formic acid 
(FA) were purchased from Sigma-Aldrich (St. Louis, 
MO). Sequencing grade endoproteinases Arg-C and 
Asp-N were purchased from Roche (Indianapolis, IN). 
Recombinant SPOP protein was purchased from Ori-
Gene (Rockville, MD). The VCaP prostate cancer cells 
were obtained from the American Type Culture Collec-
tion (Manassas, VA).
SPOP cell lines
Wild-type (WT) and three SPOP mutants (Y87N, F102C 
and F133V) cell lines were established by transfecting 
human embryonic kidney (HEK) 293T cells with expres-
sion constructs encoding either WT SPOP or specific 
mutant SPOP sequences [2, 3].
Protein extraction and digestion
The cell line samples were lysed in 8 M urea and 50 mM 
 NH4HCO3 with vortexing and sonication (3  ×  20  s), 
and the protein concentration was estimated using BCA 
assay (Pierce, Rockford, IL). Proteins were reduced with 
10 mM DTT at 37 °C for 1 h, and subsequently alkylated 
with 40 mM IAA at room temperature for 1 h in the dark. 
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After tenfold dilution with 100 mM Tris–HCl buffer (pH 
7.6), 500 mM  CaCl2 was added to the sample to reach a 
final concentration of 1 mM. Protein digestion was per-
formed at an enzyme-to-protein ratio of 1:50, at 37 °C for 
3 h. The enzymatic reaction was stopped by adding trif-
luoroacetic acid (TFA) solution to a final concentration 
of 0.1%. The resulting peptide digests were then cleaned 
up by C18 SPE cartridge (Supelco, Bellefonte, PA). The 
recombinant SPOP protein sample was digested in the 
same way without the lysis step.
LC–MS/MS analysis
LC–MS/MS analyses of the Arg-C and Asp-N digests 
of recombinant SPOP protein were carried out on a 
nanoACQUITY UPLC (Waters, Milford, MA) coupled 
to an Orbitrap Velos mass spectrometer (Thermo Sci-
entific). The LC separation was performed on a C18 
column with 0.1% FA in  H2O/ACN as buffer A/B at a 
gradient of 1–8% B in 0–2  min, 8–12% B in 2–20  min, 
12–30% B in 20–75  min, 30–45% in 75–97  min, and 
45–95% B in 97–100 min. The heated capillary temper-
ature and spray voltage was 350  °C and 2.2  kV, respec-
tively. Full MS spectra were recorded at a resolution of 
60,000 over the range of m/z 300–2000. Ten parent ions 
with most abundant intensity were selected for MS/MS 
using CID with a collision energy of 35V. The result-
ing raw data were searched against the UniProt human 
protein database [25] using the MSGF+ algorithm [26, 
27]. The parameter was 20  ppm tolerance for precur-
sor ion masses and 0.5  Da tolerance for fragment ions, 
with static carbamidomethylation on cysteine residues 
(+57.0215  Da) and dynamic oxidation of methionine 
residues (+15.9449  Da). The data filtering criteria is 
MSGF E < 10−8, Q < 0.01 and mass measurement error 
<20 ppm (±10 ppm).
PRISM fractionation
The PRISM pre-fractionation method has been 
described previously [21]. Briefly, peptide fractiona-
tion was performed on an in-house C18 (3  µm, 300  Å, 
Jupiter, Phenomenex, Torrance, CA) packed capil-
lary column (200 µm i.d. ×40 cm) at a flow rate 2.2 µL/
min on a Waters nanoACQUITY UPLC system. Buffers 
for high and low pH reversed-phase (RP) fractionation 
were 10 mM of ammonium formate (pH 9) in  H2O/90% 
ACN (A/B), 0.1% FA in  H2O/ACN (A/B) and 0.1% TFA 
in  H2O/ACN (A/B), respectively. The LC gradient was 
0.5% B in 0–35  min, 0.5–20% B in 35–37  min, 20–55% 
B in 37–107 min and 55–90% B in 132–135 min. Forty-
five micrograms of protein digests were injected for each 
PRISM run. The 1-min fractions were collected in vials 
of a 96-well plate and diluted to 20 µL with water for the 
next dimensional LC-SRM analysis.
SRM assay development
The SRM transitions of each target peptide were opti-
mized separately in direct infusion mode on a TSQ Van-
tage triple quadrupole mass spectrometer (Thermo Fisher 
Scientific). The predominant charge states of a peptide 
were selected as parent ions. Then, collision energy (CE) 
was ramped for each charged precursor to get the most 
intense fragments. Optimal CE value was determined by 
calculating the average value of three CE measurements. 
The transitions and optimal CE values were further vali-
dated by LC-SRM analysis of the heavy peptide standards 
spiked in a VCaP digest. Transition with low MS signal 
and high interference level were removed.
The method for determination of the calibration curve 
and the definition of the limit of detection (LOD) and 
limit of quantification (LOQ) has been described previ-
ously [5], with the addition of Arg-C digests from VCaP 
cell line at a final concentration of 1 µg/µL as a matrix, 
as described below. The reverse response curve for each 
SPOP peptide was generated by varying the amount of 
heavy peptide with a constant amount of light peptide 
(5  fmol/µL for the peptide in the non-mutant region, 
10  fmol/µL for peptides covering potential mutant site 
F102 or F133 and 20 fmol/µL for a peptide including pos-
sible mutant site Y87). The twelve-point response curves 
(0.05, 0.1, 0.25, 0.5, 1, 2.5, 5, 10, 25, 50, 100 and 250 fmol/
µL for heavy peptides in non-mutant region, and twofold 
and fourfold of each concentration data point for heavy 
peptides containing mutation site F102/F133 and Y87, 
respectively) covered more than 2 orders of magnitude. 
Three replicates of each data point were analyzed.
LC‑SRM analysis
All LC-SRM experiments were performed on a nanoAC-
QUITY UPLC coupled to TSQ Vantage MS instrument, 
with 4.5  µL of sample injection for each measurement. 
0.1% FA in water and 0.1% in 90% ACN were used as 
buffer A and B, respectively. Peptide separations were 
performed by an in-house C18 (3  µm, 300  Å, Jupi-
ter) packed capillary column (75  µm i.d. ×40  cm) at 
a flow rate of 350  nL/min using gradient of 0.5% B in 
0–14.5  min, 0.5–15% B in 14.5–15.0  min, 15–40% B in 
15–30 min and 45–90% B in 30–32 min. The heated cap-
illary temperature and spray voltage was set at 350 °C and 
2.4 kV, respectively. Both the Q1 and Q3 were set as 0.7 
FWHM. A scan width of 0.002 m/z and a dwell time of 
10 ms were used. All the SRM data were analyzed by Sky-
line Software [28].
Results
Peptide selection
In contrast to wild-type proteins, peptide selection for 
mutant proteins is constrained to those peptides that 
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cover the mutation sites. Consequently, some candidate 
peptides may not meet the “gold standard”, e.g., 6–20 AA 
in length, good LC elution, and strong MS signal, which 
is typically considered for selection of target peptides. 
The most frequent SPOP mutations in prostate can-
cer are located at seven distinct AA residues (e.g., Y87, 
F102, W131 and F133) clustered in the MATH domain 
(AA 31–166) [2, 29]. The AA sequence of SPOP has eight 
lysine (K) and three arginine (R) residues between the 
first (Y87) and last mutation site (K134) in the MATH 
domain (shown in Fig.  1). Use of trypsin for digestion 
of SPOP is therefore impractical for LC-SRM analy-
sis as most of the resulting tryptic peptides that include 
the mutation sites are too short. Short peptides often 
have weak retention on commonly used C18 RPLC col-
umn, and the choice of transitions for short peptides is 
much more limited (i.e., lower specificity). Additional 
file  1: Table S1 shows the peptide candidates cover-
ing the seven potential SPOP mutation sites generated 
by in silico digestion. Six of seven tryptic peptides have 
peptide length of less than 6 AA (Additional file 1: Table 
S1). Lys-C digestion has similar limitations due to a large 
number of lysine residues in this region.
Arg-C, on the other hand, specifically hydrolyzes pro-
teins and peptide bonds at the C-terminal side of argi-
nine residues; unlike trypsin, Arg-C does not cleave at 
the C-terminal of lysine residues. The result of in silico 
digestion indicates that the Arg-C peptides can cover the 
majority of the SPOP mutation sites (Additional file  1: 
Table S1). Besides Arg-C, Asp-N which cleaves peptide 
bonds at the N-terminal of aspartic acid (D) or glutamic 
acid (E) residues was also considered. All the Asp-N 
peptides covering the mutation sites are appropriate in 
length for SRM measurement (Additional file  1: Table 
S1). To determine which enzymatic digestion generates 
more MS-responsive peptides that cover the mutation 
sites, these two proteases were used to digest recombi-
nant SPOP protein, followed by LC–MS/MS analysis 
of the digests. Additional file  2: Figure S1 shows a heat 
map of the spectral counts of SPOP peptides generated 
by the two enzymatic digestions. For both conditions, 
the identification of peptides in the mutation region was 
more difficult compared to the non-mutation areas. The 
sequence coverage and relative peptide abundance by 
Arg-C in the entire protein, especially in the mutation 
region (Fig. 1), is much higher than that of Asp-N diges-
tion; Arg-C also produced a total of 162 unique peptides, 
compared to 86 by Asp-N, demonstrating the superior 
performance of Arg-C digestion for producing surro-
gate peptides for the SPOP protein isoforms. Therefore, 
Arg-C was selected for SPOP proteolysis, and PRISM-
SRM assays for a total of 16 SPOP peptide candidates 
were developed, including 11 mutation sites (Y87C/N, 
F102C, K129C, D130H, W131C/G, F133L/V/S and 
K134N) [2] and their related WT counterparts, as well as 
two “normal” peptides shared by all protein isoforms in 
the non-mutation region.
Transition selection and validation
Typically, the most intensive and interference-free pre-
cursor and fragment ions are selected as the transitions 
for the target peptides. However, transition selection 
for mutant proteins can be challenging, due to the high 
similarity in AA sequence between the point mutation 
peptides and its normal form, such that they generate 
similar series of fragment ions, especially if the mutation 
site is near the C- or N-terminus. In this situation, distin-
guishing between mutant and normal peptides relies on 
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Fig. 1 Heat map of spectral counts of the peptides generated from recombinant SPOP protein MATH domain by Arg‑C and Asp‑N digestion. The 
AAs shown in red and underlined fonts represent the reported potential mutant sites. The sequence of SPOP is obtained from UniProt [25]. The heat 
map for spectral counts of peptides generated from full‑length SPOP protein shown in Additional file 2: Figure S1
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the precursor m/z; if their precursor m/z values are also 
close, then additional information, such as the difference 
in LC elution time, is also needed.
Most of the Arg-C peptides covering the SPOP muta-
tion site(s) have multiple internal lysine residues, and 
hence carry multiple charges with the 4+ precursor ions 
being the most intense (Table 1). Compared to the com-
mon doubly charged precursors, the m/z differences 
between mutant and normal precursors with 4+ charges 
are much smaller. For instance, the mutant peptide VNPK-
GLDEESKDYLSLCLLLVSCPKSEVR and its WT peptide 
VNPKGLDEESKDYLSLYLLLVSCPKSEVR only have a 
small m/z difference of 0.7581, and share many intensive 
fragment ions, which is insufficient to distinguish them 
solely by the SRM transitions. In our LC-SRM analysis of 
the peptide mixture, we found two peaks appeared in the 
extracted ion chromatogram (XIC) of peptide VNPK-
GLDEESKDYLSLYLLLVSCPKSEVR (Peaks 1 and 2 in 
Additional file  3: Figure S2A), which was caused by co-
scanning of the WT peptide and its mutant counterpart 
VNPKGLDEESKDYLSLCLLLVSCPKSEVR. On the other 
hand, only Peak 1 was detected in the XIC of VNPKGL-
DEESKDYLSLCLLLVSCPKSEVR (Additional file  3: Fig-
ure S2B), suggesting that Peak 1 belongs to this mutant 
peptide while Peak 2 belongs to the WT peptide VNPK-
GLDEESKDYLSLYLLLVSCPKSEVR. The final validated, 
optimal transitions for the 16 target peptides are listed in 
Additional file 4: Table S2.
Matrix effects on peptide loss
During the transition validation, we also noted that 
some hydrophobic SPOP peptides showed a poor 
response in the LC-SRM analysis of the neat peptide 
mixture. One of the examples is that peptide VNPKGLD 
EESKDYLSLYLLLVSCPKSEVR and its two mutant 
forms VNPKGLDEESKDYLSLCLLLVSCPKSEVR and 
VNPKGLDEESKDYLSLNLLLVSCPKSEVR were barely 
detected in the neat peptide mixture (Additional file  5: 
Figure S3A). We postulated that the lack of a protective 
matrix in the pure peptide stocks might contribute to 
substantial loss of the highly hydrophobic peptides. To 
test this hypothesis, we prepared the heavy peptide stock 
solutions in a VCaP cell digest with a final concentration 
of 0.2 µg/µL and repeated the analysis. Indeed, all three 
heavy peptides from the stock solution with matrix were 
detected with much better response (Additional file  5: 
Figure S3B).
The matrix effect on all the 16 target peptides was fur-
ther investigated by plotting the peptide recovery (peak 
area ratio of no-matrix versus with-matrix) to their theo-
retical hydrophobicity calculated based on AA sequence 
using the Thermo Fisher on-line peptide analyzing tool 
(http://www.thermofisher.com; Additional file  6: Figure 
S4). Overall, three of the peptides with hydrophobic-
ity  <30 showed high recovery (>70%); six peptides with 
hydrophobicity  >32.5 (color zone) have ~10% recovery; 
three peptides with hydrophobicity >40 (the examples in 
Additional file 3: Figure S2) have only 2% recovery. This 
result demonstrated that adding a matrix with a similar 
peptide concentration level for LC-SRM analysis (0.2 µg/
µL) to the pure peptide stocks is an effective way to 
reduce peptide loss, especially for the hydrophobic pep-
tides. Moreover, it also helped to reduce run-to-run vari-
ation, e.g., the CV of H/L ratio of peptides reduced from 
4 to 34% using no-matrix stocks (mean CV ~14%) to 
<10% using the stocks with matrix (mean CV ~4%), dem-
onstrating the importance of matrix on the stock stability 
of these Arg-C SPOP peptides. Two other matrices, tryp-
tic digests of LNCaP prostate cancer cells and Shewanella 
oneidensis, were also tested and they were equally effec-
tive in reducing the loss of hydrophobic peptides and 
improving the reproducibility of LC-SRM analysis (data 
not shown).
Peptide loss in PRISM fractionation
Regular LC-SRM could not detect many of the low abun-
dance SPOP proteins in the cells (see Additional file  7: 
Figure S5). Therefore, PRISM-SRM, a highly sensitive 
Table 1 LOD and LOQ (fmol/µg of total protein) of the PRISM-SRM assays for WT and mutant SPOP proteins
tR retention time
Peptide Charge Transition Production type LOD fmol/µg LOQ fmol/µg tR min
VNPKGLDEESKDYLSLYLLLVSCPKSEVR 4+ 838.7−962.2 y8 0.4 1 30.0
VNPKGLDEESKDYLSLNLLLVSCPKSEVR 4+ 826.4−962.5 y8 0.2 0.4 28.4
AKFKFSILNAKGEETKAMESQR 4+ 629.1−721.3 y6 0.5 1 24.5
AKCKFSILNAKGEETKAMESQR 4+ 632.3−721.3 y6 0.5 1 23.8
FVQGKDWGFKKFIR 4+ 439.8−895.6 y7 0.2 0.5 25.6
FVQGKDWGVKKFIR 4+ 427.8−847.6 y7 0.1 0.2 24.5
LADELGGLWENSR 2+ 730.4−918.4 y8 0.05 0.1 27.9
SLASAQCPFLGPPR 2+ 750.9−943.5 y8 0.05 0.1 26.1
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targeted quantification technique which has enabled 
quantification of low-abundance proteins at pg/mL 
level in depleted plasma/serum or low 100  s copies per 
cell levels [30], was used for developing the SPOP muta-
tion assays. Compared to regular LC-SRM, PRISM-
SRM allows for up to 50 times more loading (maximum 
50 µg) of samples in the first dimension high pH (pH 9) 
reversed-phase LC separation (with optional concatena-
tion for multiplexing), specific target peptide-containing 
fractions with much-reduced sample complexity are then 
analyzed by LC-SRM, leading to as high as 100 times 
improvement in sensitivity [21].
However, not all peptides can take full benefit of the 
PRISM separation (e.g., due to potential peptide loss in 
the additional dimension of separation). We evaluated 
the recovery of the peptides after fractionation by com-
paring the heavy peptide intensity of PRISM-SRM to that 
of straight LC-SRM analysis. It was noted that all the pep-
tides in the mutant region had a PRISM-SRM/LC-SRM 
ratio of ≤1. Three peptides with significant sample loss 
have pI of ~10 or higher (Additional file 8: Figure S6). We 
reason that the sample loss may be caused by the strong 
interaction between the positively charged basic peptides 
and the negatively charged silanol groups on the sepa-
ration media in the high pH separation condition (pH 
9). To determine if acidic RP conditions can reduce the 
PRISM peptide loss, we tested 0.1% FA and 0.1% TFA in 
 H2O/ACN as the mobile phases A/B for the first-dimen-
sion PRISM fractionation. Indeed, the results showed 
that FA mobile phases slightly improved the overall 
peptide detection, while TFA mobile phases provided a 
significant boost of peptide signals, in particular for the 
peptides having high pI values (Additional file  8: Figure 
S6). Thus, 0.1% TFA mobile phases were selected for the 
optimal condition of SPOP PRISM fractionation. Overall, 
PRISM-SRM of these long, multiple-internal-lysine-con-
taining Arg-C peptides did not provide even higher (e.g., 
>100×) improvement in sensitivity like the case of other 
“regular” peptides, presumably due to the reduced matrix 
protection in the PRISM fractions (i.e., the majority of 
the non-target peptides are removed) and the reduced 
orthogonality with the second-dimension acid RPLC 
separation. However, it still enabled much needed more 
sensitive measurements of the SPOP mutation peptides 
comparing to regular straight LC-SRM analysis.
PRISM‑SRM quantification
To quantify the mutant SPOP peptides, the response 
curve, LOD and LOQ for eight SPOP peptides (three 
peptides represented as both WT and mutant versions, 
plus the two “common” peptides in the non-mutated 
region) in PRISM-SRM assay was determined. The result 
was shown in Fig.  2 and Table  1. Although the Arg-C 
digested SPOP peptides in the mutation region are longer 
and more hydrophobic, the mutation PRISM-SRM assays 
still showed an excellent linear dynamic range of more 
than 2 orders of magnitude (Fig. 2). The LOD and LOQ 
for SPOP peptides range from 0.05 to 0.5 and 0.1 to 1.0 
fmol/µg, respectively. The median CV for each peptide 
in triplicate PRISM-SRM runs was  ≤10%, demonstrat-
ing good reproducibility. Furthermore, among all the 
mutant SPOP peptides, FVQGKDWGVKKFIR derived 
from mutant  SPOPF133V has the best sensitivity for quan-
tification by PRISM-SRM with the lowest LOD and LOQ 
values (Table 1). Interestingly, the  SPOPF133V mutation is 
the most frequently mutated residue in prostate cancer 
(~50% of the total SPOP mutations) [5]. Therefore, our 
newly developed point-mutation-specific PRISM-SRM 
assays could be very useful to study the most commonly 
observed SPOP protein mutations in prostate cancer.
The optimized PRISM-SRM assay was applied to quan-
titatively analyze protein digests from SPOP cell line sam-
ples. A total of 5 cell lines including HEK293T cells and 
HEK293T cells expressing either SPOP-WT or SPOP-
mutant (Y87N, F102C, and F133V) were tested. The 
XICs of SPOP peptides in HEK293T cell lines expressing 
SPOP-WT and three SPOP mutations by PRISM-SRM 
analysis are shown in Fig. 3 and Additional file 9: Figure 
S7. All the endogenous peptides, both WT and mutant 
peptides, were detected clearly in the corresponding 
transfected cell line samples, but not in the non-trans-
fected HEK293T control sample (data not shown). Com-
pared to the LC-SRM analysis, the increased loading 
and reduced background interference in PRISM-SRM 
enabled the detection of peptides in even the cell lines 
with lower SPOP protein expression, such as VNPK 
GLDEESKDYLSLYLLLVSCPKSEVR and AKFKFSIL 
NAKGEETKAMESQR in WT and F133V cells. The CV 
of peptide VNPKGLDEESKDYLSLNLLLVSCPKSEVR 
and AKCKFSILNAKGEETKAMESQR was calculated as 
3.7 and 4.6%, respectively. The CV for the mutant pep-
tide FVQGKDWGVKKFIR’s was 16.7% due to the lower 
abundance of the endogenous protein. Overall, the CV of 
each SPOP peptide in all samples was ≤20% showing good 
reproducibility of the PRISM-SRM assay.
The SPOP protein concentrations were calculated based 
on the peak area ratio and the response curve (Table  2). 
Although detected, peptide AKFKFSILNAKGEETKAMES 
QR in the SPOP-WT and F133V cell lines was below LOQ 
and could not be quantified. From the two peptides in the 
non-mutant region (LADELGGLWENSR and SLASAQCPF 
LGPPR), it can be seen that the overall expression of WT and 
F133V is 10–20 times lower than that of Y87N and F102C 
in the corresponding cell lines. The mutant peptides VNPK 
GLDEESKDYLSLNLLLVSCPKSEVR, AKCKFSILNAKGE 
ETKAMESQR and FVQGKDWGVKKF in the three 
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transfected cell lines were determined to be 61.4, 9.4 and 
1.8 fmol/µg of total protein, respectively.
Discussion
Studies on protein mutations have relied heavily on iso-
form-specific antibodies. However, it is very challenging 
to develop high-quality antibodies for specific recogni-
tion of protein isoforms without cross-reactivity. Com-
pared to antibody-based methods, MS-based targeted 
proteomics has higher specificity, shorter lead times 
and much higher success rates in developing sensitive, 
specific and accurate assays for protein isoform quanti-
fication. The high quality heavy isotope-labeled peptide 
standards needed for highly confident and precise quan-
tification can also be obtained readily from commer-
cial vendors. Moreover, front-end peptide enrichment 
methods such as SISCAPA (stable isotope standards 
and capture by anti-peptide antibodies) [31] and PRISM 
enable protein quantification at low ng/mL to 50 pg/mL 
levels in blood plasma/serum, rivaling the sensitivity 
of ELISA assays. Thus, targeted proteomics provides 
a valuable alternative for preclinical validation of pro-
tein isoforms (e.g., mutation, splice variant, gene fusion, 
and post-translational modification) as potential disease 
biomarkers.
The SRM quantification of mutant SPOP proteins has 
some unique challenges that are inherently associated 
with its AA sequence: there are seven potential muta-
tion sites distributed in a 49-AA region containing eight 
lysine and three arginine residues. This precludes the 
conventional enzymatic digestion methods using trypsin 
or Lys-C because most of the enzymatically cleaved pep-
tides covering the mutation site(s) are too short to be 
analyzed by LC–MS/MS with good specificity. Arg-C 
produces longer peptides that cover all the mutation sites 
(14–29 AA). However, these peptides are in general less 
responsive in electrospray ionization, compared to typi-
cal tryptic peptides that are selected for SRM analysis 
(e.g., 6–20 AA). The presence of multiple internal lysine 
residues also causes the most MS-responsive precursor 
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Fig. 2 The response curve of the PRISM‑SRM assays (in log–log scale) for eight SPOP peptides (black WT; red mutant): VNPKGLDEESKDYLSLYLLLVSC 
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KKFIR (c) and LADELGGLWENSR/SLASAQCPFLGPPR (d)
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ions to carry 4+ charges (note that the Asp-N peptides 
also have multiple internal lysine residues and in general 
provide even lower MS signal). This results in small dif-
ferences in m/z of the precursor ions, hence the risk of 
having the mutant and WT peptides co-scanned (causing 
reduced specificity), as well as decreased fragmentation 
efficiency, because the beam-type collision in the triple 
quadrupole MS instrument is not as efficient as the elec-
tron transfer dissociation available on the hybrid Orbit-
rap instrument for fragmenting long, highly charged 
Fig. 3 XICs of SPOP WT peptides in mutant region detected in HEK293T cell lines expressing WT SPOP cell line (a) and their corresponding mutant 
counterparts detected in SPOP Y87N, F102C and F133V mutant cell lines (b) using PRISM‑SRM (AA shown in red font indicates mutation site). XICs 
for all the peptide candidates (details available in Additional file 4: Table S2) in four SPOP cell lines were shown in Additional file 9: Figure S7
Table 2 Quantification of SPOP peptides in HEK293T cells expressing WT and mutant SPOP proteins by PRISM-SRM
The peptide concentrations are shown in fmol/µg of total protein
NQ not quantified
Cell line VNPKGLDEESKDYLSLYLLL‑
VSCPKSEVR
AKFKFSILNAKGEET‑
KAMESQR
FVQGKDWGFKKFIR LADELGGLWENSR SLASAQCPFLGPPR
WT Y87N WT F102C WT F133V WT WT
SPOPWT 1.3 ± 0.1 NQ 2.4 ± 0.3 6.2 ± 0.2 21.4 ± 0.5
SPOPY87N 61.4 ± 2.3 37.6 ± 2.4 43.6 ± 2.3 180 ± 1 435 ± 9
SPOPF102C 98.6 ± 1.0 9.4 ± 0.6 61.1 ± 7.7 188 ± 2 468 ± 26
SPOPF133V 4.3 ± 0.4 NQ 1.8 ± 0.4 13.9 ± 0.03 29.1 ± 0.4
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peptides. Moreover, these long Arg-C peptides are also 
highly hydrophobic, causing significant peptide loss in 
peptide standard handling and PRISM fractionation.
The following procedures were used to overcome these 
difficulties and substantially improve the assay quality: 
(1) high-resolution LC separation helps to fully resolve 
the mutant and WT peptides, eliminating potential 
ambiguity and interference in peptide quantification; (2) 
adding protein digests as a protective matrix to the pure 
peptide stocks effectively reduces loss of the hydrophobic 
Arg-C peptide internal standards; (3) use of TFA instead 
of the basic mobile phases in the PRISM fractionation 
significantly improves recovery of the SPOP peptides that 
have high pI values; and (4) PRISM-SRM provides higher 
sensitivity than regular LC-SRM for SPOP mutation 
analysis. As a result, all the PRISM-SRM assays showed 
a linear dynamic range of more than two orders of mag-
nitude, with LOQ of 0.2–1 fmol/μg of total protein in the 
cell lysate for the mutation site(s)-containing peptides. In 
this report, the three most frequent SPOP mutations in 
prostate cancer, Y87N, F102C, and F133V, were unam-
biguously confirmed in respective transfected HEK293T 
cell lines using these PRISM-SRM assays. Since the SPOP 
mutations behave as loss of function mutants in cell line 
experiments [32], it will be important to determine in 
future experiments the relative abundance of mutant and 
wild type SPOP protein present in prostate tumor tissues.
Conclusions
In summary, PRISM-SRM provides a sensitive, iso-
form-specific, multiplexed, and antibody-independent 
approach for quantification of SPOP mutations at the 
protein level, which holds great promise for the verifica-
tion of the mutant SPOP proteins as biomarkers for pros-
tate cancer.
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